Topic · Head and Neck Cancer Studies
Most cited papers in Head and Neck Cancer Studies
What are the most cited papers in Head and Neck Cancer Studies?
The most cited paper in Head and Neck Cancer Studies is "Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer" (K. Kian Ang, Jonathan Harris, Richard H. Wheeler et al., 2010), with 6,617 citations. Next come "Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer" (6,330) and "Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck" (5,189).
Showing 50 of 100 papers. Every paper with more than 1,113 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer K. Kian Ang, Jonathan Harris, Richard H. Wheeler et al. · New England Journal of Medicine | 7 Jun 2010 | 6,617 |
| 2 | Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer Núbia Muñóz, Francesc Xavier Bosch, Sílvia de Sanjosé et al. · New England Journal of Medicine | 5 Feb 2003 | 6,330 |
| 3 | Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck Robert Louis Ferris et al. · New England Journal of Medicine | 9 Oct 2016 | 5,189 |
| 4 | Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck James A. Bonner, Paul M. Harari, J. Giralt et al. · New England Journal of Medicine | 8 Feb 2006 | 5,137 |
| 5 | Head and neck squamous cell carcinoma Daniel E. Johnson, Barbara Ann Burtness, Charles René Leemans et al. · Nature Reviews Disease Primers | 26 Nov 2020 | 4,223 |
| 6 | Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer Jan B. Vermorken, Ricard Mesı́a, Fernando Rivera et al. · New England Journal of Medicine | 10 Sep 2008 | 3,762 |
| 7 | Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States Anil K. Chaturvedi, Eric A. Engels, Ruth M. Pfeiffer et al. · Journal of Clinical Oncology | 4 Oct 2011 | 3,651 |
| 8 | Global epidemiology of oral and oropharyngeal cancer Saman Warnakulasuriya · Oral Oncology | 19 Sep 2008 | 3,484 |
| 9 | Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective Francesc Xavier Bosch, M. Michele Manos, N. Munoz et al. · JNCI Journal of the National Cancer Institute | 7 Jun 1995 | 3,439 |
| 10 | Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study Barbara Ann Burtness et al. · The Lancet | Nov 2019 | 3,344 |
| 11 | Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck Jay Scott Cooper, Thomas F. Pajak, Arlene A. Forastiere et al. · New England Journal of Medicine | 5 May 2004 | 3,297 |
| 12 | Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer Jacques Bernier, Christian Domenge, Mahmut Özsahin et al. · New England Journal of Medicine | 5 May 2004 | 3,214 |
| 13 | Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer Arlene A. Forastiere, Helmuth Goepfert, Moshe H Maor et al. · New England Journal of Medicine | 26 Nov 2003 | 3,192 |
| 14 | Nasopharyngeal carcinoma Yu‐Pei Chen, Anthony T.�C. Chan, Quynh‐Thu Le et al. · The Lancet | 7 Jun 2019 | 3,186 |
| 15 | Evidence for a Causal Association Between Human Papillomavirus and a Subset of Head and Neck Cancers Maura L. Gillison · JNCI Journal of the National Cancer Institute | 3 May 2000 | 3,121 |
| 16 | Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients Jean‐Pierre Pignon, Aurélie Le Maître, E. Maillard et al. · Radiotherapy and Oncology | 15 May 2009 | 3,081 |
| 17 | Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial Carole Fakhry, William H. Westra, S. Li et al. · JNCI Journal of the National Cancer Institute | 12 Feb 2008 | 2,814 |
| 18 | Case–Control Study of Human Papillomavirus and Oropharyngeal Cancer Gypsyamber DʼSouza, Aimée R. Kreimer, Raphael P. Viscidi et al. · New England Journal of Medicine | 9 May 2007 | 2,706 |
| 19 | Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial Joël Shapiro et al. · The Lancet Oncology | 6 Aug 2015 | 2,615 |
| 20 | The molecular biology of head and neck cancer Charles René Leemans, Boudewijn J.M. Braakhuis, Ruud H. Brakenhoff · Nature reviews. Cancer | 16 Dec 2010 | 2,566 |
| 21 | Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data Jean‐Pierre Pignon, Jean Bourhis, Christian Domenge et al. · The Lancet | Mar 2000 | 2,479 |
| 22 | Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma Thierry O. Philip, Cesare Guglielmi, Anton Hagenbeek et al. · New England Journal of Medicine | 7 Dec 1995 | 2,458 |
| 23 | Worldwide burden of cancer attributable to HPV by site, country and HPV type Catherine de Martel, Martyn Plummer, Jérôme Vignat et al. · International Journal of Cancer | 4 Apr 2017 | 2,393 |
| 24 | Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer David Cunningham, Naureen Starling, Sheela Rao et al. · New England Journal of Medicine | 2 Jan 2008 | 2,326 |
| 25 | Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. Muhyi Al‐Sarraf, Michael Leo LeBlanc, Padmini Giri et al. · Journal of Clinical Oncology | Apr 1998 | 2,245 |
| 26 | Head and neck cancer Athanassios E. Argiris, Michalis V. Karamouzis, David Raben et al. · The Lancet | May 2008 | 2,240 |
| 27 | Head and Neck Cancer Everett E. Vokes, Ralph R. Weichselbaum, Scott Michael Lippman et al. · New England Journal of Medicine | 21 Jan 1993 | 2,223 |
| 28 | Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review Aimée R. Kreimer, Gary M. Clifford, Peter A. Boyle et al. · Cancer Epidemiology Biomarkers & Prevention | Feb 2005 | 2,191 |
| 29 | Head and Neck Cancer Laura Q.M. Chow · New England Journal of Medicine | 2020 | 2,145 |
| 30 | Smoking and drinking in relation to oral and pharyngeal cancer. William J. Blot, Joseph K. McLaughlin, Deborah M. Winn et al. · PubMed | Jun 1988 | 2,020 |
| 31 | Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival James A. Bonner, Paul M. Harari, J. Giralt et al. · The Lancet Oncology | 12 Nov 2009 | 1,984 |
| 32 | Chemoradiotherapy of Locally Advanced Esophageal Cancer Jay Scott Cooper, Matthew D. Guo, Arnold M. Herskovic et al. · JAMA | 5 May 1999 | 1,982 |
| 33 | A Comparison of Multimodal Therapy and Surgery for Esophageal Adenocarcinoma T. N. Walsh, N. Noonan, Donal P. Hollywood et al. · New England Journal of Medicine | 15 Aug 1996 | 1,961 |
| 34 | Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials Guglielmo Ronco, Joakim Dillner, K. Miriam Elfström et al. · The Lancet | 2 Nov 2013 | 1,845 |
| 35 | HPV-associated head and neck cancer: a virus-related cancer epidemic Shanthi Marur, Gypsyamber DʼSouza, William H. Westra et al. · The Lancet Oncology | 6 May 2010 | 1,839 |
| 36 | Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501) Jacques Bernier, Jay Scott Cooper, Thomas F. Pajak et al. · Head & Neck | 2005 | 1,782 |
| 37 | Nomenclature and classification of potentially malignant disorders of the oral mucosa Saman Warnakulasuriya, Newell Walter Johnson, Isaäc van der Waal · Journal of Oral Pathology and Medicine | 26 Jul 2007 | 1,775 |
| 38 | Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial Tanguy Y. Seiwert, Barbara Ann Burtness, Ranee Mehra et al. · The Lancet Oncology | 28 May 2016 | 1,766 |
| 39 | An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck Cancer David J. Adelstein, Yi Li, George L. Adams et al. · Journal of Clinical Oncology | 28 Dec 2002 | 1,759 |
| 40 | Mortality due to cancer treatment delay: systematic review and meta-analysis Timothy Paul Hanna, Will D. King, Stéphane Thibodeau et al. · BMJ | 4 Nov 2020 | 1,749 |
| 41 | A Prognostic Score for Advanced Hodgkin's Disease Dirk Hasenclever et al. · New England Journal of Medicine | 19 Nov 1998 | 1,749 |
| 42 | Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study Ezra E.W. Cohen et al. · The Lancet | 30 Nov 2018 | 1,731 |
| 43 | Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer Jan Baptist Vermorken, Éva Remenár, Carla van Herpen et al. · New England Journal of Medicine | 24 Oct 2007 | 1,726 |
| 44 | Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial Christopher M. Nutting, James P. Morden, Kevin Joseph Harrington et al. · The Lancet Oncology | 14 Jan 2011 | 1,721 |
| 45 | Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer Marshall R. Posner et al. · New England Journal of Medicine | 24 Oct 2007 | 1,713 |
| 46 | Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer Fabio Landoni, Andrea Maneo, Alessandro Colombo et al. · The Lancet | Aug 1997 | 1,704 |
| 47 | Head and neck cancers—major changes in the American Joint Committee on cancer eighth edition cancer staging manual William M. Lydiatt, Snehal G. Patel, Brian P O'Sullivan et al. · CA A Cancer Journal for Clinicians | 27 Jan 2017 | 1,687 |
| 48 | Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis Katrin Marie Sjoquist, Bryan Henry Burmeister, Bernard Mark Smithers et al. · The Lancet Oncology | 21 Jun 2011 | 1,669 |
| 49 | Cervical Human Papillomavirus Prevalence in 5 Continents: Meta‐Analysis of 1 Million Women with Normal Cytological Findings Laia Bruni, Mireia Díaz, Xavier Castellsagué et al. · The Journal of Infectious Diseases | 10 Nov 2010 | 1,666 |
| 50 | Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women Jorma A. Paavonen et al. · The Lancet | Jul 2009 | 1,663 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.